Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Retraction Note

Retraction Note: Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2

Authors: Dian-Hui Xiu, Gui-Feng Liu, Shao-Nan Yu, Long-Yun Li, Guo-Qing Zhao, Lin Liu, Xue-Feng Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Excerpt

Retraction Note: J Exp Clin Cancer Res 38, 94 (2019) …
Metadata
Title
Retraction Note: Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2
Authors
Dian-Hui Xiu
Gui-Feng Liu
Shao-Nan Yu
Long-Yun Li
Guo-Qing Zhao
Lin Liu
Xue-Feng Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02121-3

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Review

Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis

Review

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

Review

Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular

Correction

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

Review

Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations

Correction

Correction to: HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFβ axis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits